nonlinear PK: highest dose ⇔ strength [Regulatives / Guidelines]
THX for your explanations!
❝ ❝ Multiple strengths of drugs with nonlinear PK (grater than proportional increase in AUC)?
❝ ❝ EMA: highest strength.
❝ ❝ FDA: highest therapeutic dose.
❝
❝ I think that FDA also recommend highest strength, same as EMA. See line 316–319 in the draft guidance. Where did it mention highest therapeutic dose?
See lines 325–326 of the draft (and also the 2003 guidance). Applicable if linear PK is documented. I was referring to Davit et al.* (all authors of the FDA). Excerpt:
[…] generally the highest dose strength be used for in vivo BE studies, unless reasons of safety justify using a lower strength. In the case of drug substances that are characterized by nonlinear PK over the clinical dosing range, Canada, the EMA, USA, and WHO specify which dose strength should be used in these cases, depending on the type of nonlinearity and the underlying mechanism.
Dose strength used in the in vivo studies
- Similarities
All recommend that generally in vivo studies should be performed on the highest strength, unless reasons of safety justify use of a lower strength
- Differences
Some jurisdictions specify which strength should be used for drugs with nonlinear PK over the clinical dosing range, as follows
EMA: the strength to be used depends upon the type of nonlinearity and the underlying causes
If the nonlinearity is characterized by greater than proportional increases in AUC with increasing dose, conduct the BE studies on at least the highest strength
USA: the strength to be used depends upon the type of nonlinearity
If the nonlinearity is characterized by greater than proportional increases in AUC with increasing dose, conduct the BE studies on at least the highest therapeutic dose (38)
- Davit B, Braddy AC, Conner DP, Yu LX. International Guidelines for Bioequivalence of Systemically Available Orally Administered Generic Drug Products: A Survey of Similarities and Differences. AAPS J. 2013; 15(4): 974–90. doi:10.1208/s12248-013-9499-x.
38. FDA. Draft Guidance on Phenytoin Sodium. 2008.
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- Pharmacokinetic parameters CL, Vd and F mmw 2017-05-06 11:07 [Regulatives / Guidelines]
- Pharmacokinetic metrics CL, Vd and F Helmut 2017-05-06 12:14
- Pharmacokinetic metrics CL, Vd and F Shuanghe 2017-05-08 16:16
- CFDA 2016 BE-GL Helmut 2017-05-09 13:52
- CFDA 2016 BE-GL Shuanghe 2017-05-10 13:03
- nonlinear PK: highest dose ⇔ strengthHelmut 2017-05-10 15:17
- highest dose ⇔ strength for dummies d_labes 2017-05-10 15:41
- highest dose ⇔ strength for dummies Helmut 2017-05-10 15:45
- highest dose ⇔ strength for dummies d_labes 2017-05-10 16:20
- highest dose ⇔ strength for dummies Helmut 2017-05-10 16:28
- highest dose ⇔ strength for dummies d_labes 2017-05-11 16:31
- highest dose ⇔ strength for dummies mmw 2017-05-15 06:53
- highest dose ⇔ strength for dummies Helmut 2017-05-10 16:28
- highest dose ⇔ strength for dummies d_labes 2017-05-10 16:20
- highest dose ⇔ strength for dummies Helmut 2017-05-10 15:45
- highest dose ⇔ strength for dummies d_labes 2017-05-10 15:41
- nonlinear PK: highest dose ⇔ strengthHelmut 2017-05-10 15:17
- CFDA 2016 BE-GL Shuanghe 2017-05-10 13:03
- CFDA 2016 BE-GL Helmut 2017-05-09 13:52
- Pharmacokinetic metrics CL, Vd and F Shuanghe 2017-05-08 16:16
- Pharmacokinetic metrics CL, Vd and F Helmut 2017-05-06 12:14